Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer

Bo Lu, Yi Mu, Carolyn Cao, Fenghua Zeng, Sylke Schneider, Jiahui Tan, Jim Price, Jun Chen, Michael Freeman, and Dennis E. Hallahan

Departments of 1 Radiation Oncology, and 2 Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee; 3 Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California; and 4 Abbott Laboratories, Abbott Park, Illinois

ABSTRACT

Expression of survivin is elevated in most malignancies, especially in radiation-resistant cell lines. In this study, we investigated how radiation affects survivin expression in primary endothelial cells as well as in malignant cell lines. We found that 3 Gy significantly reduced survivin protein level in human umbilical vein endothelial cells (HUVECs) but not in tumor cell lines. Flow cytometry studies suggest that the down-regulation of survivin is independent of cell cycle. In addition, survivin mRNA level was also down-regulatable by irradiation. However, it was abrogated by actinomycin D-mediated inhibition of gene transcription. Luciferase reporter gene assays suggest that irradiation suppressed the survivin promoter. p53 overexpression reduced survivin expression, but overexpression of a p53 mutant failed to abolish the radiation-induced down-regulation in HUVECs. Alteration of p53 status in Val138 lung cancer cell line also failed to restore the radiation-inducible down-regulation. Overexpression of survivin in 293 cells prevented apoptosis induced by irradiation and increased cell viability after irradiation. The inhibition of survivin using antisense oligonucleotides caused a significant decrease in cell viability of irradiated H460 lung cancer cells. These data suggest that radiation transcriptionally down-regulates survivin in HUVECs. This regulatory mechanism is defective in malignancies and is not mediated by p53. Survivin overexpression may lead to resistance to radiotherapy by inhibiting apoptosis and enhancing cell viability. The inhibition of survivin results in sensitization of H460 lung cancer cells to radiation. These studies suggest that survivin may be a target for cancer therapy.

INTRODUCTION

Inhibitor of apoptosis protein belongs to a family of proteins that regulate cell death (1). Survivin is the smallest member of the mammalian inhibitor of apoptosis family. It inhibits caspase 9 and blocks apoptotic pathway (2). The most notable feature of survivin expression is its absence in most terminally differentiated normal tissues, but it is highly expressed in malignancies and embryonic tissues (3–4). Survivin overexpression in malignancies was shown to be independent of mitotic indices or Ki67 reactivity (5). Survivin expression is up-regulated in all phases of cell cycle, and the cancer-specific activity of survivin promoter was detected both in vivo and in vitro (6). p53 is one of the regulators, which transcriptionally down-regulates survivin through binding a bipartite p53-responsive element in the survivin promoter (7).

Survivin is also highly expressed in neuroangiogenesis (3–4). Survivin expression in endothelial cells was necessary to sustain the angiopoietin-1 (12). Clinically, high levels of survivin have been observed in some tumors (10). Its expression was also associated with decreased overall survival, increased recurrences, and resistance to therapy (4). Therefore, we examined the effects of irradiation on both protein and mRNA levels of survivin in cultured human umbilical vein endothelial cells (HUVECs) and tumor cell lines. We found that survivin is transcriptionally down-regulated by irradiation in HUVECs, but not in malignant cell lines. This transcriptional suppression is not mediated by p53. Furthermore, we found that overexpression of survivin led to radiation resistance, whereas the inhibition of survivin resulted in the radiosensitization of H460 lung cancer cells.

MATERIALS AND METHODS

Cell Culture, Adenoviral Vectors, and Chemicals. HUVECs were obtained from Clonetics and were maintained in endothelial basal medium-2 (EBM-2) medium supplemented with endothelial growth medium (EGM-2) and 5% fetal bovine serum. Various cell cancer cell lines were obtained from American Type Culture Collection and cultured in their required media. Val138 cell (a gift from Dr. Maureen Murphy, Fox Chase Cancer Center, Philadelphia, PA) originates from human lung adenocarcinoma cell line H1299 stably transfected with temperature-sensitive p53 mutant. Val138 cells were cultured in DMEM (DMEM, Invitrogen) plus 10% fetal bovine serum, 100 units/ml penicillin and streptomycin, and 0.8 mg/ml Geneticin. HEK 293 cells (American Type Culture Collection) transfected with pCDNAhis-survivin or pcDNAhis vector were selected in DMEM with 10% FCS and 0.5 mg/ml G418 (Invitrogen). Single cell clones overexpressing survivin or neomycin control were confirmed by immunoblotting. Actinomycin D (Sigma) was used at a final concentration of 5 μg/ml. Irradiation (3 Gy) was given 1 h after the drug was added, by use of a Colbalt-60 radioactive source. Adenoviral vectors overexpressing LacZ and p53 were gifts from Dr. Shuang Huang, The Scripps Research Institute (San Diego, CA).

Western Immunobots. Cells were treated with 3 Gy and various drugs and collected at various time points. The cells were counted and then were washed with ice-cold PBS twice before the addition of lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and leupeptin). Protein concentration was quantified by the Bio-Rad method. Equal amounts of protein were loaded into each well and separated by 14% SDS-PAGE gel, followed by transfer onto nitrocellulose membranes. Membranes were blocked by use of 10% nonfat dry milk in PBS for 2 h at room temperature. The blots were then incubated with the rabbit-antihuman [survivin (R&D systems), p53 and phospho-p53-serine 15 (Cell Signal), cleaved caspase 3 (Cell Signal)] antibodies overnight at 4°C. Donkey antirabbit IgG secondary antibody (1:1000; Amersham) was incubated for 1 h at room temperature. Immunoblots were developed by using the enhanced chemiluminescence (ECL) detection system (Amersham) according to the manufacturer’s protocol and autoradiography.

Flow Cytometry. Cells were trypsinized, rinsed once, resuspended in PBS, and fixed with 4% paraformaldehyde (PFA) for 30 min. Cells were washed with ice-cold PBS and resuspended in 50 μg/ml propidium iodide (Sigma) with 40 kilounits (KU)/ml of DNase-free RNase (Stratagene, La Jolla, CA). Fixed cells were analyzed by FACScan. The percentage of cells in each phase was calculated using ModFit software.

Real-Time Quantitative Reverse Transcription-PCR. Total RNA was isolated from cell culture, using a Qiagen RNA extraction kit. After RNA isolation, cDNA was prepared from each sample as described previously (14). Quantification of cDNA and an internal reference gene (β-actin) was conducted using a fluorescence-based real-time detection method [ABI PRISM 7700 Sequence Detection system (TaqlMan); Perkin-Elmer Applied Biosystems, Foster City, CA], as described previously (14–15). All of the quantitative reverse transcription-PCR experiments were performed as triplicates. The PCR mixture consisted of 600 nmol/liter each primer, 200 nmol/liter probe (sequences used are given below, in “!”Plasmid, AS Oligonucleotides, Transfection and Luciferase Assays), 5 units of AmpliTaq Gold polymerase, 200 μM each...
buffer A containing a reference dye, to a final volume of 25 μL. The luciferase activity was measured from 1.6 to 72 h after incubation. The entire experiment was carried out in triplicates. The luciferase activity was normalized to total protein levels. The entire experiment was carried out in triplicates. The luciferase activity was normalized to total protein levels.

Plasmid, AS Oligonucleotides, Transfection and Luciferase Assays. Spi plasmid (a gift of Dr. M. Murphy from Fox Chase Cancer Center) contains 1.1 kb of the survivin promoter in a Luciferase reporter construct, pCR2.1. The underlined nucleotides are 2-′O-methoxymethyl modifications. Subconfluent H460 cells were transfected with either of the oligonucleotides, using Lipofectin with a mixture of Lipofectin (Life Technologies, Inc., Baltimore, MD) and oligonucleotides in Opti-MEM medium (Life Technologies, Inc.) at a ratio of 3 μL Lipofectin/ml medium per 100 nm oligonucleotide. After 4 h of incubation, cells were replaced by the regular complete medium.

### Table 1  Primer and probe sequences for reverse transcription PCR

<table>
<thead>
<tr>
<th>Primer and probe sequences</th>
<th>Primer and probe sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survivin</td>
<td></td>
</tr>
<tr>
<td>Forward primer</td>
<td>5′-TGC CCC GAC GTG GCC-3′</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>5′-CAG TTC TTG AAT GTA GAG ATG CGG T-3′</td>
</tr>
<tr>
<td>Probe</td>
<td>6FAM-5′-CCC GGT ACC CCT TTC TCA AGG ACC-3′-TAMRA</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
</tr>
<tr>
<td>Forward primer</td>
<td>5′-TGAGCGGCTGCTACATT-3′</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>5′-TCCTAAAGTCTACGCTAATT-3′</td>
</tr>
<tr>
<td>Probe</td>
<td>6FAM-5′-ACCAACAGGCGGCGAGG-3′-TAMRA</td>
</tr>
<tr>
<td>COX2</td>
<td></td>
</tr>
<tr>
<td>Forward primer</td>
<td>5′-GCTCAACATGATGTTGCAATC-3′</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>5′-GCTCCGCTCGCTACGATG-3′</td>
</tr>
<tr>
<td>Probe</td>
<td>6FAM-5′-GCCCAGCATTGACGATG-3′-TAMRA</td>
</tr>
</tbody>
</table>

dATP, dCTP, and dGTP, 400 μM dUTP, 5.5 mM MgCl₂, and 1× TaqMan buffer A containing a reference dye, to a final volume of 25 μL (all of the reagents were supplied by Perkin-Elmer Applied Biosystems). Cycling conditions were 50°C for 10 s and 95°C for 10 min, followed by 46 cycles at 95°C for 15 s and 60°C for 1 min. Colon, liver, and lung RNAs (all from Stratagene, La Jolla, CA) were used as control calibrators on each plate. Primer and probe sequences of the analyzed genes are shown in Table 1.

Plasmid, AS Oligonucleotides, Transfection and Luciferase Assays. Spi plasmid (a gift of Dr. Jennifer Pietenpol, Vanderbilt University, Nashville, TN), Sp1 plasmid (2.5 μg) or 2.5 μg of Sp1 plus 2.5 μg of p53 mutant plasmid was transiently transfected into 60% confluent HUVECs grown in 3.5-cm plates, by a F1 Targetef (Targeting systems). After 24 h, cells were irradiated with 3 Gy. They were collected at 0, 4, 8, and 16 h after irradiation. Cells were lysed and luciferase assays were performed as the protocol from the manufacturer (Promega) on a Monolight 3010 Luminometer (PharMingen). Luciferase activity was normalized to total protein levels. The entire experiment was carried out in triplicates. The luciferase activity was measured from 1.6 μg of protein lysates. Antisense (AS) oligonucleotides were synthesized (Qiagen, Inc) using the following sequences: the survivin AS oligonucleotides: 5′-TGTCG-TGTTCTGTGAATT-3′; the mismatch control oligonucleotide: 5′-TAAGC-TGTGC-TATGTT-3′; the survivin target oligonucleotide: 5′-CAG TTC TTG AAT GTA GAG ATG CGG T-3′

#### RESULTS

Irradiation Reduces Survivin Expression in Primary Endothelial Cells but not in Malignant Cells. Survivin plays a critical role in cell viability. To determine the time-dependent expression of survivin in the irradiated endothelial cells and tumor cell lines, we extracted total protein at 5, 15, and 30 min, and at 1, 2, 4, 16, 24 h. Fig. 1 shows the autoradiograph of Western immunoblots. Survivin expression became undetectable at 16 h (Fig. 1A) and remained undetectable at 24 h. However, 3 Gy failed to down-regulate survivin in all of the cancer cell lines that were tested, as shown in Fig. 1B. To determine whether the decrease of survivin is a result of reduction in mitotic activity, we examined cell-cycle distribution at various time points to determine whether there is an increase of nonmitotic cells beyond 16 h postirradiation. HUVECs were irradiated with 3 Gy and were col-
lected at 0, 4, and 24 h. Cells were fixed with 70% ethanol and stained with propidium iodide. Flow cytometry analyses showed no significant variation of G2-M cells at these time points, as shown in Fig. 1C.

**Down-Regulation of Survivin in HUVECs Is Mediated by Transcriptional Suppression.** To examine whether the survivin mRNA level is altered after radiation treatment, we irradiated HUVECs with 3 Gy and collected at 0, 1, 2, 4, 16, and 24 h. Total cellular RNA was isolated. Quantification of survivin mRNA and β-actin (internal reference) mRNA was performed using real-time reverse transcription-PCR. As shown in Fig. 2A, the relative level of survivin mRNA began to decrease at 4 h after irradiation and was further reduced by more than 50% at 24 h. However, this was not observed in colorectal cancer cell lines (SW480 and SW620), as shown in Fig. 2B.

To determine whether the decrease of mRNA is a result of mRNA instability, we treated HUVECs with actinomycin D alone or together with 3 Gy added 1 h later. As shown in Fig. 3, A and B, survivin mRNA was stable after either treatment, whereas Cox-2 mRNA decreased to one-third at 2 h after either treatment. To confirm that the down-regulation of survivin is contributed by reduced transcription, HUVECs were transfected by a luciferase reporter under the control of 1.1 kb survivin promoter fragment. Transfected cells were irradiated and collected at 0, 4, 8, and 16 h after irradiation. As shown in Fig. 3C, luciferase activity was significantly reduced at the various time points after irradiation. These data suggest radiation decreases the promoter activity of survivin gene.

**Role of p53 in Down-Regulating Survivin.** DNA damage from irradiation triggers activation and increase of p53 (18). We therefore studied the p53 status in HUVECs after irradiation. HUVECs were irradiated with 3 Gy and were collected at various time points. Protein extracts were made and analyzed by Western blotting. As shown in Fig. 4A, p53 phosphorylation increased within 15 min of irradiation, whereas the level of total p53 protein did not change. To determine whether overexpression of p53 has an impact on survivin levels in endothelial cells, we used the expression vector Ad.p53. Adenovirus-mediated overexpression of wild-type p53 decreased survivin mRNA level at 24 h after HUVECs were transduced (Fig. 4B). To determine whether p53 mediates the down-regulation of survivin by irradiation, we studied Val138 cell, a lung adenocarcinoma cell line stably transduced with a temperature-sensitive mutant of p53. Cells were cultured at either 39 degrees (predominantly expressing mutated p53) or 32 degrees (predominantly expressing wild-type p53). As shown in Fig. 4C, survivin levels were higher when mutant p53 was expressed. Irradiation did not decrease survivin mRNA even when p53 was predominantly wild type. To confirm this result, we cotransfected an expression plasmid of mutant p53 with the luciferase reporter driven by the 1-kb survivin promoter. The promoter activity was increased in general in the presence of mutant p53, but the radiation-induced down-regulation was not abolished (Fig. 4D).

**Survivin As a Target for Radiation Sensitization.** To determine whether survivin affects radiation sensitivity, we compared the extent of apoptosis induced by 3 Gy, using 293 cell lines that are stably transfected with a plasmid overexpressing survivin. As shown in Fig. 5A, cleaved caspase 3 was detected in irradiated control (293 cells without survivin overexpression). In comparison, it was not detected after 3 Gy in survivin-overexpressing cells. This suggests that a high level of survivin may confer resistance to radiation-induced apoptosis (Fig. 5A). Similar experiments were performed to determine cell proliferation by 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. As shown in Fig. 5B, irradiation failed to inhibit cell proliferation and viability in survivin-overexpressing cells.

To study the biological effects of survivin inhibition in cancer, we

---

**Fig. 2. Down-regulation of survivin mRNA by 3 Gy in human umbilical vein endothelial cells (HUVECs), but not in colorectal cancer cells.** Cells were irradiated with 3 Gy. Total RNA was extracted at the indicated time points after the irradiation treatment. The RNA samples were reverse-transcribed to cDNA and were quantified by Taqman real-time PCR. Shown are the relative mRNA levels of survivin in reference to β-actin. A, HUVECs; B, SW 480 and SW 620.
used an AS approach to inhibit survivin expression in H460 lung cancer cells. Either anti-survivin (AS, i.e., antisense) or a missense (mismatch) control oligonucleotide was transiently transfected using Lipofectin. Survivin expression was determined by Western blotting 48 h after transfection. As shown in Fig. 6A, AS oligonucleotide against survivin attenuated survivin expression, compared with the mismatch oligonucleotide. To determine whether inhibition of survivin affects cell survival in irradiated H460 cells, H460 cells transfected with either AS or mismatch were then treated with or without 3 Gy. The 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was performed 48 h after irradiation. As shown in Fig. 6B, both 3 Gy alone and AS alone resulted in a 20% reduction of cell viability. However, concurrent survivin inhibition and irradiation caused a 2–3-fold reduction of cell viability. To confirm this result, we performed the clonogenic assay. As shown in Fig. 6C, the inhibition of survivin by AS significantly down-shifted the survival curve.

Fig. 6. Inhibition of survivin enhanced radiation effects in H460 lung cancer cells. A, survivin expression was attenuated 48 h after H460 cells were transfected with anti-survivin antisense oligonucleotide (AS). Mismatch (MS) is the control oligonucleotide. B, H460 cells were transfected with either AS or MS oligonucleotides. 24 h later, the transfected cells were treated with or without 3 Gy. The 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was performed 48 h after irradiation. Each graph, the mean ± SD from three repeated experiments. C, transfected H460 cells or nontransfected control were treated with 0–5 Gy. After 2 weeks, colonies were stained and colonies over 50 cells were scored. Data are shown as the mean ± SD.
of H460 after 2 Gy and 5 Gy. These data suggest that the inhibition of survivin leads to radiation sensitization in H460 lung cancer cells.

**DISCUSSION**

In this study, we have shown that survivin is transcriptionally down-regulated by radiation in normal human endothelial cells. However, this mechanism is defective in malignant cell lines. p53 is shown to affect survivin levels in general, but it does not mediate radiation-inducible suppression of survivin. We have shown that overexpression of survivin leads to radiation resistance by inhibiting apoptosis and promoting cell survival. Inhibition of survivin in H460 lung cancer greatly enhanced the cytotoxic effects of radiotherapy.

Both cell-cycle-dependent and cell-cycle-independent regulation of survivin have been described (4). It is believed that the cell-cycle dependent regulation is mediated transcriptionally by a cell-cycle-dependent element/cell-cycle gene homology region in the survivin promoter (18). Posttranscriptionally, proteasome-dependent destruction may lead to the decrease of survivin during interphase (19). However, survivin expression was increased by interleukin 11 and angiot tensin II in endothelial cells, independent of cell-cycle progression, via phosphorylation of signal transducer and activator of transcription 3 (STAT3) or phosphatidylinositol 3-kinase (20). In the present study, transcriptional down-regulation of survivin in HUVECs was induced by irradiation and was independent of cell cycle. However, a similar decrease of survivin was not detected in various cancer cell lines. We found that the protein level of survivin decreased significantly at 16 h postirradiation in HUVECs. But its promoter activity was reduced at 4 h after irradiation. However, at the same time point, the mRNA level of survivin had only a slight drop, presumably because of the stability of its mRNA.

We explored the mechanism by which survivin is down-regulated in HUVECs. We found that radiation induced a down-regulation of survivin mRNA. Radiation had decreased the activity of survivin promoter without altering its mRNA stability. This suggests that survivin is transcriptionally down-regulated by irradiation. Because p53 may bind to the survivin promoter and suppress its transcription (7), we examined the role of p53 in the down-regulation of survivin. We have shown that p53 can be activated in irradiated HUVECs. Overexpression of wild-type p53 in HUVECs resulted in a lower level of survivin mRNA. However, we found that restoration of p53 function failed to down-regulate survivin mRNA in Val138 lung cancer cells. In addition, cotransfection of mutant p53 failed to abolish the down-regulation of survivin promoter in HUVECs. However, increased survivin expression was found in the presence of mutant p53 in both HUVECs and Val138 cells. This suggests that p53 affects survivin level in general but does not mediate transcriptional suppression by irradiation. Another possible mechanism of down-regulating survivin protein by irradiation is through its phosphorylation. It has been shown that Thr34 of survivin is phosphorylated by p34CDC2, a process that is critical for survivin function (21). Inhibition of this phosphorylation event by cyclin-dependent kinase inhibitors results in the defective phosphorylation of survivin by cyclin-dependent kinase p34CDC2, dissociation of survivin-caspase 9 complex, and induction of apoptosis (21). Inhibition of p34CDC2 by cyclin-dependent kinase inhibitors such as Purvalanol (Purv.A) and flavopiridol significantly enhance the apoptosis and antitumor activity of Taxol and Adriamycin, respectively, in a breast cancer xenograft model (22, 34). Adenoviral-mediated overexpression of T34A mutant results in tumor reduction in xenograft models of breast cancer and melanoma (21, 34, 35). We found that anti-survivin oligonucleotides significantly enhanced cytotoxic effects of radiation in lung cancer cells.

In summary, our results suggest that survivin is down-regulated by radiation in endothelial cell but not in various cancer cell lines. The combination of survivin inhibition and irradiation resulted in significantly decreased cell survival of cancer cells. Additional studies are ongoing to determine the transcription factors that mediate radiation-induced suppression of survivin as well as to validate survivin as a target for radiation sensitization in animal models of lung cancer.

**ACKNOWLEDGMENTS**

We thank Allie Fu for technical support.

**REFERENCES**

Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer

Bo Lu, Yi Mu, Carolyn Cao, et al.


Updated version Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/8/2840

Cited articles This article cites 34 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/8/2840.full#ref-list-1

Citing articles This article has been cited by 16 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/8/2840.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.